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ABSTRACT: The vinyl ether benzyloxycarbonyl (VeZ) protecting group is selectively cleaved by treatment with tetrazines via an 
inverse electron-demand Diels–Alder reaction. This represents a new orthogonal protecting group for solid-phase peptide synthesis, 
with Fmoc-Lys(VeZ)-OH as a versatile alternative to Fmoc-Lys(Alloc)-OH and Fmoc-Lys(Dde)-OH for the synthesis of cyclic 
peptides, as demonstrated by the synthesis of melanotan II (MTII) and a constrained BAD BH3 peptide analogue. 
Peptides are valuable scaffolds due to their intrinsic biological 
and chemical properties.1 Cyclic peptides often show good in 
vivo stability, while demonstrating enhanced biological activi-
ties compared to their linear counterparts.2 Given the growing 
interest in these constrained molecules as therapeutic and bio-
medical tools, there is a demand for efficient synthetic   ap-
proaches.3 In solid-phase peptide synthesis (SPPS), protecting 
groups orthogonal to Fmoc are typically used to temporarily 
mask side-chain functionalities to enable controlled synthesis 
via the so-called Fmoc/tBu approach.4-6 For the generation of 
cyclic or complex peptides, such as those decorated on their 
side-chains,7 the demands are more complex with the need for 
another tier of orthogonality, typically provided by Alloc8 or 
Dde (or ivDde),9 both which have their limitations. The cleav-
age of the Alloc group requires the use of palladium salts, po-
tentially complicating the purification of peptides aimed at bi-
ological and medical applications, while the standard condi-
tions used for the removal of the Dde (2–5% hydrazine in 
DMF) are not compatible with the Fmoc group and will reduce 
the Alloc group, furthermore, the Dde moiety can undergo mi-
gration.10, 11 Therefore, efforts have been made to develop a 
variety of other orthogonal cleavage strategies that offer mild 
cleavage conditions for the selective deprotection of side-
chain groups.12-17 
Inverse electron-demand Diels–Alder (invDA) reactions be-
tween tetrazines and electron-rich dienophiles have been wide-
ly used in bioconjugation chemistry.18, 19 Recently, they have 
found applications in drug delivery/prodrug activation20-23 and 
protein activation chemistries,24 with the tetrazine acting as a 
trigger, which upon the invDA reaction starts a cascade pro-
cess resulting in the liberation of the cargo and formation of 
pyridazine as a side product. For example, Robillard devel-
oped a biorthogonal system using a trans-cyclooctene as a 
strained dienophile that allowed drug release through an elim-
ination reaction mediated by a tetrazine.23 Li used an invDA-
mediated deprotection strategy for bioorthogonal protein acti-
vation where the ε-amino group of a catalytic lysine residue 
was likewise modified with a trans-cyclooctene making the 
target protein inactive until uncaged by a tetrazine.24 Our 
group reported a polymeric drug delivery system, which fea-
tured a vinyl ether as a dienophile that, upon activation, un-
caged a phenol(ate) that underwent subsequent 1,6-elimination 
and cargo liberation.20 Herein, we introduce the vinyl ether 
benzyloxy carbonyl (VeZ) group as a tetrazine-cleavable pro-
tecting group that was used to mask the ε-amino group on ly-
sine, with Fmoc-Lys(VeZ)-OH used as a Fmoc/tBu-orthogonal 
protected building block in the solid-phase synthesis of cyclic 
peptides. 
Three VeZ derivatives were synthesized with zero, one or two 
methoxy groups incorporated into the phenyl ring as increas-
ing election density was envisioned to promote the invDA re-
action by reducing the highest occupied molecular orbital 
(HOMO) and lowest unoccupied molecular orbital (LUMO) 
gap with the diene.19, 25 The VeZ moiety was prepared via vi-
nylation of the phenolic hydroxy group in the corresponding 
aldehydes 1a–c using the vinyl boronic anhydride pyridine 
complex and copper(II) acetate,26 followed by reduction of the 
aldehydes 2a–c with NaBH4 to give the benzylic alcohols 3a–
c, which were subsequently transformed into the correspond-
ing carbonates 4a–c by treatment with 4-nitrophenyl chlo-
roformate (Scheme 1). Carbonates 4a–c were coupled onto 
Fmoc-Lys-OH and Cbz-Lys-OH, with transient protection of 
the carboxyl group with MSTFA,27 allowing incorporation of 
the VeZ protecting group on the side chain through a carba-
mate linkage to give 5a–d (24–55% over four steps) (Scheme 
1). 
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Treatment of the VeZ protecting group with a tetrazine was 
envisioned to trigger a cascade process starting with the re-
moval of the vinyl ether group to liberate the phenol(ate), fol-
lowed by amino liberation through a 1,6-elimination reaction 
(Figure 1). Initially, 5a (5.6 mM) was treated with the widely 
used tetrazine, 3,6-di-2-pyridyl-1,2,4,5-tetrazine20 (17 mM), in 
DMF at various temperatures (up to 60 °C); however, no reac-
tion of the vinyl ether was observed after 24 h (Table 1). 
Scheme 1. Synthesis of the VeZ protected lysines 5a–d 
 
 
Since water is known to dramatically accelerate Diels–Alder 
reactions, perhaps by promoting hydrophobic interactions be-
tween the dienophile and tetrazine or acting as a general 
acid,19 5a was treated with tetrazine in 10% H2O/DMF (v/v) at 
60 °C. Under these conditions, 80% conversion of the vinyl 
compound into the phenol derivative 6 was observed (as de-
termined by HPLC-MS), with 6 isolated in 65% yield after 
column chromatography. The introduction of two methoxy 
groups (compound 5b) resulted in slower conversion into the 
corresponding phenolate, whereas 5a (one methoxy group) 
and 5c (no methoxy groups) showed comparable reactivity in 
reactions monitored by 1H NMR (Supporting Information (SI), 
Figure S1–S3). 
It was somewhat surprising that the phenol intermediate 6 was 
isolable. The subsequent 1,6-elimination from 6 was promoted 
by increasing the water content in the reaction mixture; how-
ever, even 50% H2O/DMF (v/v) only resulted in a 1:1.4 ratio 
of the phenol 6 and the desired Fmoc-Lys-OH (Table 1). Pro-
tonation of the tetrazine and its consequent increased electron 
deficiency is known to enhance reaction rates in invDA reac-
tion chemistry,19 while a lower pH would also promote  
 
  
Figure 1. Mechanism of tetrazine-mediated vinyl ether decaging 
and amine liberation. 
Table 1. Tetrazine-mediated deprotection of Fmoc-
Lys(VeZ)-OH 5aa 
 
entry temp (°C) solvent 
time  
(h) 
conv 
(%) 
ratio 
6:Lysd 
1 rt DMF 24 0 – 
2 40 DMF 24 0 – 
3 60 DMF 24 0 – 
4 rt 10% H2O/DMF 18 2 1:0 
5 40 10% H2O/DMF 18 58 1:0 
6 60 10% H2O/DMF 18 80 1:0 
7 60 25% H2O/DMF 18 92 1:1 
8 60 50% H2O/DMF 18 100 1:1.4 
9 60 50% bufferb/DMF 18 100 0:1 
10 40c 50% buffer/DMF 2 33 2:1 
11 40c  50% buffer/DMF 4 43 2:1 
12 60c 50% buffer/DMF 1 48 1:1 
13 60c 50% buffer/DMF 2 58 1:3 
14 60c 50% buffer/DMF 4 71 1:10 
aReaction conditions: Fmoc-Lys(VeZ)-OH 5a (5.6 mmol), 3,6-di-
2-pyridyl-1,2,4,5-tetrazine (17 mmol). bSodium citrate buffer (100 
mM, pH 5). cThe reaction was carried out under µW irradiation. d 
Fmoc-Lys-OH. 
 
protonation of the carbamate, thereby enhancing the 1,6-
elimination reaction. Thus, when the reaction with the te-
trazine was carried out at 60 °C for 18 h using a 1:1 (v/v) mix-
ture of pH 5 sodium citrate buffer and DMF, full conversion of 
compound 5a into the corresponding ε-amino free lysine was 
observed (Table 1, entry 9). This reaction could be accelerated 
by performing the deprotection reaction under microwave 
(µW) irradiation conditions (60 °C for 4 h) giving the VeZ 
 
 
3 
deprotected lysine as the main product (longer irradiation 
times did not improve conversion due to rapid degradation of 
the tetrazine). 
These optimized VeZ deprotection conditions were directly 
transferred onto the solid support using the water compatible 
resin ChemMatrix (loading 1 mmol/g, 35–100 mesh, loaded 
with an Fmoc-Rink-amide linker) that was subsequently func-
tionalized with Cbz-Lys(VeZ)-OH (5d) (Scheme 2). Using 3 
×1 h deprotection cycles with fresh tetrazine solution. Subse-
quent coupling with Fmoc-Gly-OH and cleavage of the resin, 
gave the dipeptide 7 in quantitative yield, showing the effi-
cient cleavage of the vinyl ether and the subsequent 1,6-
elimination reaction.  
 
Scheme 2. Tetrazine-mediated deprotection on the solid-
phase 
 
 
To explore possible epimerization under these deprotection 
conditions, two diastereoisomeric peptides Ac-Phe-Lys(Ac)-
NH2 8a and Ac-phe-Lys(Ac)-NH2 8b were synthesized on a 
ChemMatrix resin that had been functionalized with a Rink 
linker, with subsequent coupling of Fmoc-Lys(VeZ)-OH. Up-
on deprotection of the Fmoc group, either Fmoc-Phe-OH or 
Fmoc-phe-OH were coupled to the lysine followed by the 
cleavage of the VeZ group using the tetrazine-mediated proto-
col described above. Acetylation of the free amino groups and 
cleavage from the resin gave the diastereoisomers 8a and 8b 
that were clearly resolved by HPLC and HPLC analysis 
showed no evidence of epimerization (Figure S5).  
In order to evaluate the orthogonality and compatibility be-
tween the VeZ group and other protecting groups commonly 
used in peptide chemistry (e.g. Fmoc, Dde, Allyl, Alloc, Boc), 
as well as standard cleavage protocols, stability studies were 
carried out in solution alongside 5a and 5d. The VeZ group 
was readily cleaved from the lysine side chain under strongly 
acidic conditions (95% TFA), but was stable in 2% TFA and 
20% HFIP for more than 3 h (Table S1). The VeZ group was 
also compatible with standard Fmoc-based SPPS conditions 
(carbodiimide-actived couplings and 20% piperidine in DMF), 
Alloc removal (Pd(PPh3)4, PhSiH3 in DMF), Dde removal (2% 
hydrazine in DMF and NH2OH.HCl/imidazole in NMP/DMF), 
confirming its suitability in peptide synthesis. However, the 
Alloc group was not stable upon treatment with tetrazine (4 h 
µW irradiation at 60 °C), whereas the S-trityl group was ob-
served to be robust under these conditions (Table S2).  
To test its versatility, Fmoc-Lys(VeZ)-OH 5a was applied to 
the synthesis of two cyclic peptides, melanotan II (9) (MTII)28 
and a constrained BAD BH3 peptide analogue 10,29 both ex-
amples of side-chain to side-chain lactam-bridge peptides 
(Scheme 3). MTII 9 (Ac-Nle-c[Asp-His-phe-Arg-Trp-Lys]-
NH2) is a potent agonist of melanocortin receptors,28 while 10 
(Ac-1Nal-Arg-c[Lys-Nle-Ala-Asp-Asp]-Phe-NH2) is a poten-
tial anticancer agent that exerts its activity by inhibiting Bcl-
2.29 The fully protected linear peptides were synthesized on a 
Rink-amide functionalized ChemMatrix resin using a Fmoc-
based solid-phase chemistry with DIC and Oxyma as the cou-
pling combination and Fmoc-Lys(VeZ)-OH 5a as a building 
block. After the selective cleavage of the 2-phenylisopropyl 
group (O-2-PhiPr) from the side chain of aspartic acid using 
3% TFA in CH2Cl2, the VeZ group was cleaved using the
 
Scheme 3. Side chain to side chain cyclization of linear peptides using the tetrazine-cleavable VeZ as an orthogonal side-
chain protecting group 
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tetrazine-mediated protocol (3 × 1 h of dipyridyl tetrazine (30 
mM) in 1:1 (v/v) sodium citrate buffer and DMF at 60 
°C, µW). On-resin cyclization was achieved using Py-
BOP/HOBt/DIPEA in DMF and was followed by deprotection 
of the side chains and cleavage from the solid support by TFA, 
followed by purification by preparative HPLC, giving the cy-
clic peptides 9 and 10 in 47% and 39% isolated yields, respec-
tively. 
In conclusion, the benzyloxycarbonyl vinyl ether (VeZ) pro-
tecting group has been introduced as a temporary masking 
group for amino functionalities during solid-phase peptide 
synthesis. It can be removed by treatment with a tetrazine via 
devinylation and subsequent 1,6-elimination chemistries. The 
VeZ protecting group was stable under standard Fmoc-based 
SPPS conditions and could be selectively removed under rela-
tive mild conditions without affecting other common side 
chain protecting groups or the Rink-amide linker. The ap-
plicability of the approach was demonstrated by the solid-
phase synthesis of two biologically relevant cyclic peptides. It 
is interesting to note that the tetrazine-mediated inverse Diels–
Alder reaction was hugely accelerated by the presence of even 
10% water and that the 1,6-elimination reaction of the “safety-
catch linker”30 was not spontaneous and was promoted by 
acidic conditions.  
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